NANOHMICS INC — Department of Health and Human Services SBIR Phase I: NCI
NANOHMICS INC — SBIR Phase I award from Department of Health and Human Services.
- Amount
- $299,999
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase I
- Topic
- NCI
- NAICS
- —
- Place of performance
- TX
- Period
- —
Description
Cell free nucleic acid cfNA biomarkers circulating in the blood have the potential to serve as simple rapid and non invasive diagnostic indicators As such cell free biomarkers have emerged in the forefront of cancer diagnostic research with the promise of improved disease state prognostication therapy resistance monitoring and metastasis or recurrence determination using a simple blood test A multiplexed cancer diagnostic device with the sensitivity to detect low molecular copies of biomarkers of specific cancer genotypes simplicity of blood plasma lateral flow strip assays and robustness of nucleic acid microarrays that can be packaged as a comprehensive genotype cancer diagnostic panel would greatly improve early detection rates of recurrence and metastasis and guide the oncology treatment plan To overcome barriers limiting the adoption of high density microassays in diagnostic settings Arrion Sciences an early stage biotechnology and sensor development subsidiary Austin TX working in collaboration with LC Sciences Houston TX DRS Technologies the University of Texas at Austin Microelectronics Research Center UT MRC and Dr Sylvie Beaudenon Huibregste is proposing to develop a multiplexed biodetection array platform with nucleic acid probes for detection of clinically significant cell free breast cancer biomarkers in the blood